Brief: Senti Bio Announces Positive Initial Clinical Data In Phase 1 Clinical Trial Of Senti-202, A Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy For The Treatment Of Relapsed/Refractory Hematologic Malignancies Including AML

Senti Biosciences Holdings

02/12/2024 12:25

Dec 2 (Reuters) - Senti Biosciences  SNTI.O :
    * SENTI BIO ANNOUNCES POSITIVE INITIAL CLINICAL DATA IN
PHASE 1
CLINICAL TRIAL OF SENTI-202, A LOGIC GATED, SELECTIVE
CD33/FLT3-TARGETING CAR-NK CELL THERAPY FOR THE TREATMENT OF
RELAPSED/REFRACTORY HEMATOLOGIC MALIGNANCIES INCLUDING AML
    * SENTI BIOSCIENCES INC - SENTI-202 GENERALLY WELL-TOLERATED
WITH
CONSISTENT ADVERSE EVENT PROFILE
    * SENTI BIOSCIENCES INC - DOSE ESCALATION CONTINUING,
ADDITIONAL
DATA EXPECTED IN 2025

Source text:  ID:nGNX4XG7dt 
Further company coverage:  SNTI.O 

 ((Reuters.Briefs@thomsonreuters.com;))